| Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors. | Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors.
Kim JY, Kim J, Kim YI, Yang DH, Yoo C, Park IJ, Ryoo BY, Ryu JS, Hong SM., Free PMC Article | 03/4/2024 |
| Somatostatin receptor2 (SSTR2) expression, prognostic implications, modifications and potential therapeutic strategies associates with head and neck squamous cell carcinomas. | Somatostatin receptor2 (SSTR2) expression, prognostic implications, modifications and potential therapeutic strategies associates with head and neck squamous cell carcinomas.
Fan S, Zheng H, Zhan Y, Luo J, Zang H, Wang H, Wang W, Xu Y. | 01/8/2024 |
| Somatostatin Receptor Type 2 and Thyroid-Stimulating Hormone Receptor Expression in Oncocytic Thyroid Neoplasms: Implications for Prognosis and Treatment. | Somatostatin Receptor Type 2 and Thyroid-Stimulating Hormone Receptor Expression in Oncocytic Thyroid Neoplasms: Implications for Prognosis and Treatment.
Gillis A, Zheng-Pywell R, McLeod C, Wang D, Ness JM, Guenter R, Whitt J, Prolla TA, Chen H, Gonzalez ML, Rose B, Lloyd RV, Jaskula-Sztul R, Lin D., | 01/3/2024 |
| Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses. | Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses.
Fischer A, Kloos S, Maccio U, Friemel J, Remde H, Fassnacht M, Pamporaki C, Eisenhofer G, Timmers HJLM, Robledo M, Fliedner SMJ, Wang K, Maurer J, Reul A, Zitzmann K, Bechmann N, Žygienė G, Richter S, Hantel C, Vetter D, Lehmann K, Mohr H, Pellegata NS, Ullrich M, Pietzsch J, Ziegler CG, Bornstein SR, Kroiss M, Reincke M, Pacak K, Grossman AB, Beuschlein F, Nölting S., Free PMC Article | 09/20/2023 |
| Epigenetic regulation of SST2 expression in small intestinal neuroendocrine tumors. | Epigenetic regulation of SST(2) expression in small intestinal neuroendocrine tumors.
Klomp MJ, Refardt J, van Koetsveld PM, Campana C, Dalm SU, Dogan F, van Velthuysen MF, Feelders RA, de Herder WW, Hofland J, Hofland LJ., Free PMC Article | 06/12/2023 |
| Role of Somatostatin Receptor 2 in Nonfunctional Pancreatic Neuroendocrine Tumors: Clinicopathological Analysis of 223 Cases and Whole Exome Sequencing of a Multifocal Case. | Role of Somatostatin Receptor 2 in Nonfunctional Pancreatic Neuroendocrine Tumors: Clinicopathological Analysis of 223 Cases and Whole Exome Sequencing of a Multifocal Case.
Hu HF, Hu YH, Xu XW, Ye Z, Lou X, Zhang WH, Chen XM, Zhang Y, Yu XJ, Gao HL, Xu JY, Ji SR. | 05/1/2023 |
| Somatostatin receptor 2 in 10 different types of human non-neoplastic gastrointestinal neuroendocrine cells. | Somatostatin receptor 2 in 10 different types of human non-neoplastic gastrointestinal neuroendocrine cells.
Watanabe H, Fujishima F, Unno M, Sasano H, Suzuki T. | 04/12/2023 |
| The immunohistochemical expression of SSTR2A is an independent prognostic factor in meningioma. | The immunohistochemical expression of SSTR2A is an independent prognostic factor in meningioma.
Fodi C, Skardelly M, Hempel JM, Hoffmann E, Castaneda S, Tabatabai G, Honegger J, Tatagiba M, Schittenhelm J, Behling F., Free PMC Article | 08/13/2022 |
| Diagnostic Utility of Somatostatin Receptor 2A Immunohistochemistry for Tumor-induced Osteomalacia. | Diagnostic Utility of Somatostatin Receptor 2A Immunohistochemistry for Tumor-induced Osteomalacia.
Lee S, Hong N, Shin S, Kim SI, Yun M, Kim SK, Rhee Y. | 05/21/2022 |
| Somatostatin Receptor 2: A Potential Predictive Biomarker for Immune Checkpoint Inhibitor Treatment. | Somatostatin Receptor 2: A Potential Predictive Biomarker for Immune Checkpoint Inhibitor Treatment.
Wang A, Yuan Y, Chu H, Gao Y, Jin Z, Jia Q, Zhu B., Free PMC Article | 03/26/2022 |
| The prognostic significance of neuroendocrine markers and somatostatin receptor 2 in hepatocellular carcinoma. | The prognostic significance of neuroendocrine markers and somatostatin receptor 2 in hepatocellular carcinoma.
Murakami K, Kumata H, Miyagi S, Kamei T, Sasano H. | 02/12/2022 |
| A potential role for somatostatin signaling in regulating retinal neurogenesis. | A potential role for somatostatin signaling in regulating retinal neurogenesis.
Weir K, Kim DW, Blackshaw S., Free PMC Article | 11/13/2021 |
| Understanding the influence of lipid bilayers and ligand molecules in determining the conformational dynamics of somatostatin receptor 2. | Understanding the influence of lipid bilayers and ligand molecules in determining the conformational dynamics of somatostatin receptor 2.
Nagarajan SK, Babu S, Kulkarni SA, Vadivelu A, Devaraju P, Sohn H, Madhavan T., Free PMC Article | 11/13/2021 |
| SSTR2a is constantly expressed in lymphoepithelioma-like carcinoma with squamous differentiation other than that with glandular differentiation. | SSTR2a is constantly expressed in lymphoepithelioma-like carcinoma with squamous differentiation other than that with glandular differentiation.
Tao L, Chen Y, Huang Y, Yin W, Yu G. | 11/13/2021 |
| Octreotide inhibits secretion of IGF-1 from orbital fibroblasts in patients with thyroid-associated ophthalmopathy via inhibition of the NF-kappaB pathway. | Octreotide inhibits secretion of IGF-1 from orbital fibroblasts in patients with thyroid-associated ophthalmopathy via inhibition of the NF-κB pathway.
Kim SE, Kim J, Lee JY, Lee SB, Paik JS, Yang SW., Free PMC Article | 09/25/2021 |
| Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly. | Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly.
Soukup J, Hornychova H, Manethova M, Michalova K, Michnova L, Popovska L, Skarkova V, Cesak T, Netuka D, Ryska A, Cap J, Hána V, Hána V Jr, Kršek M, Dvořáková E, Krčma M, Lazurova I, Olšovská V, Starý K, Vaňuga P, Gabalec F., Free PMC Article | 09/25/2021 |
| The PDZ Domain Protein SYNJ2BP Regulates GRK-Dependent Sst2A Phosphorylation and Downstream MAPK Signaling. | The PDZ Domain Protein SYNJ2BP Regulates GRK-Dependent Sst2A Phosphorylation and Downstream MAPK Signaling.
Carr HS, Chang JT, Frost JA., Free PMC Article | 05/1/2021 |
| The potential of somatostatin receptor 2 as a novel therapeutic target in salivary gland malignant tumors. | The potential of somatostatin receptor 2 as a novel therapeutic target in salivary gland malignant tumors.
Meirovitz A, Shouchane-Blum K, Maly A, Bersudski E, Hirshoren N, Abrams R, Popovtzer A, Orevi M, Weinberger J. | 04/17/2021 |
| Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy. | Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy.
Lechner M, Schartinger VH, Steele CD, Nei WL, Ooft ML, Schreiber LM, Pipinikas CP, Chung GT, Chan YY, Wu F, To KF, Tsang CM, Pearce W, Morelli D, Philpott M, Masterson L, Nibhani R, Wells G, Bell CG, Koller J, Delecluse S, Yip YL, Liu J, Forde CT, Forster MD, Jay A, Dudás J, Krapp A, Wan S, Uprimny C, Sprung S, Haybaeck J, Fenton TR, Chester K, Thirlwell C, Royle G, Marafioti T, Gupta R, Indrasari SR, Herdini C, Slim MAM, Indrawati I, Sutton L, Fles R, Tan B, Yeong J, Jain A, Han S, Wang H, Loke KSH, He W, Xu R, Jin H, Cheng Z, Howard D, Hwang PH, Le QT, Tay JK, West RB, Tsao SW, Meyer T, Riechelmann H, Oppermann U, Delecluse HJ, Willems SM, Chua MLK, Busson P, Lo KW, Wollmann G, Pillay N, Vanhaesebroeck B, Lund VJ., Free PMC Article | 01/16/2021 |
| Enhancing the anti-tumour activity of (177)Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP. | Enhancing the anti-tumour activity of (177)Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP.
Cullinane C, Waldeck K, Kirby L, Rogers BE, Eu P, Tothill RW, Hicks RJ., Free PMC Article | 12/5/2020 |
| Expression of potential therapeutic target SSTR2a in primary and metastatic non-keratinizing nasopharyngeal carcinoma. | Expression of potential therapeutic target SSTR2a in primary and metastatic non-keratinizing nasopharyngeal carcinoma.
Tao L, Chen Y, Shi X, Yu G, Yin W, Huang Y. | 10/10/2020 |
| SSTR2a may be helpful to distinguish follicular dendritic cell sarcomas from inflammatory pseudotumor-like follicular dendritic cell sarcomas ... and may be a potential therapeutic target for treatment of follicular dendritic cell sarcomas | SSTR2a Is a Useful Diagnostic Marker for Follicular Dendritic Cells and Their Related Tumors.
Tao LL, Huang YH, Chen YL, Yu GY, Yin WH. | 01/11/2020 |
| Patients with neuroblastoma, including relapsed or progressive disease, showed SSTR2 expression at diagnosis | Prevalence and Clinical Correlations of Somatostatin Receptor-2 (SSTR2) Expression in Neuroblastoma.
Alexander N, Marrano P, Thorner P, Naranjo A, Van Ryn C, Martinez D, Batra V, Zhang L, Irwin MS, Baruchel S., Free PMC Article | 12/28/2019 |
| study suggests that SSTR2 might play a critical role in the aetiopathogenesis of periodontitis | Regulation of somatostatin receptor 2 by proinflammatory, microbial and obesity-related signals in periodontal cells and tissues.
Memmert S, Damanaki A, Nokhbehsaim M, Nogueira AVB, Eick S, Cirelli JA, Jäger A, Deschner J., Free PMC Article | 12/21/2019 |
| Reaults indicate that endosomal trafficking of somatostatin receptor 2 (SSTR2) is dependent on numerous regulatory mechanisms controlled by its C terminus and the retromer machinery. | Regulation of Somatostatin Receptor 2 Trafficking by C-Tail Motifs and the Retromer.
Olsen C, Memarzadeh K, Ulu A, Carr HS, Bean AJ, Frost JA., Free PMC Article | 12/21/2019 |